• Cero Therapeutics posted a net loss of $5.89 million for quarter ended March 31, 2026, widening 15.3% year over year.
• Operating loss narrowed 2.1% to $4.85 million as operating expenses edged down 2.1% to $4.85 million.
• Research and development expense fell 19.6% to $2.34 million, while general and administrative expense rose 22.7% to $2.51 million.
• Cash, restricted cash, and cash equivalents totaled $857,489 at March 31, 2026 as net cash used in operating activities improved to $2.76 million from $4.45 million a year earlier.
• Raised $456,166 of net proceeds from ELOC fundings during the quarter, with $1.5 million of net proceeds from convertible notes payable; April financings included $350,000 and $400,000 convertible promissory notes carrying 10% interest and maturing in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-057753), on May 15, 2026, and is solely responsible for the information contained therein.